Foghorn Therapeutics (FHTX), a clinical-stage biotech company with its sights set on revolutionizing oncology, surprised with top-and-bottom-line beats for Q3. The company is making significant ...

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...